IGC Pharma, Inc.
IGC Pharma, Inc. is a U.S.-based clinical-stage pharmaceutical company focused on Alzheimer’s disease and related neurodegenerative conditions. Its lead program, IGC-AD1, is in Phase 2 testing for agitation in Alzheimer’s dementia, while the company also sells a small portfolio of white-label, private-label, and branded wellness products through its Life Sciences segment.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueInvestigational Alzheimer’s and neurodegenerative disease drug candidates in preclinical and Phase 2 development.
Manufactured formulations, white-label products, and branded wellness items sold commercially.
Internal clinical development, trial operations, and related scientific work supporting pipeline advancement.
Products
Reported · share of revenue- Tolling White Labeling Service91.1 %
- Wellness and Lifestyle8.9 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
IGC Pharma sells primarily to commercial buyers of manufactured wellness and formulation products, while its core therapeutic pipeline is aimed at patients with Alzheimer’s disease and the caregivers and clinicians who influence treatment adoption. The company’s near-term revenue base is small and concentrated, with two customers each accounting for more than 10% of sales in fiscal 2025. Its longer-term value proposition is directed at physicians, patients, and healthcare systems seeking better options for agitation and other Alzheimer’s-related symptoms.
Buy white-label and private-label manufactured products for resale or distribution.
Purchase holistic health and branded products through retail and online channels.
The end market for IGC-AD1 and future neurodegenerative therapies aimed at symptom relief.
Potential collaborators that may help fund, develop, or commercialize pipeline assets.
Strategy
IGC Pharma is prioritizing advancement of IGC-AD1 through Phase 2 clinical development while building a broader Alzheimer’s pipeline, including TGR-63 and MINT-AD. Management is also trying to preserve commercial optionality by keeping a small Life Sciences product business, using internal trial operations to control costs, and seeking external capital and non-dilutive funding to support R&D.
The lead asset is the main driver of future value and clinical validation.
A broader pipeline reduces single-asset dependence and improves partnering potential.
The company remains loss-making and needs funding to sustain R&D and trials.
Lower per-patient trial costs improve capital efficiency and extend runway.
Geography
Q1/2026IGC Pharma is headquartered in the United States and manufactures products in Vancouver, Washington, which is important to its Life Sciences supply chain. The company’s reported revenue disclosures do not provide a country-by-country sales split, but its operations are clearly U.S.-centric and exposed to U.S. FDA and state-level regulatory requirements. The disposition of the Vancouver facility also affected production and fulfillment during fiscal 2025, reducing near-term commercial output.
Risks
IGC Pharma faces the typical risks of a clinical-stage biotech company: trial failure, regulatory delay, and the possibility that its lead asset never reaches commercialization. It also has a very small revenue base, concentrated customers and suppliers, and ongoing dependence on equity financing, which can dilute shareholders and increase volatility. The company’s newer digital-asset treasury policy adds mark-to-market and regulatory risk on top of its existing operating and funding risks.
- Dependence on external financingImpact: HighLikelihood: High
The company has recurring losses and limited cash, so it relies on equity raises and other funding.
Exposure - Lead program may fail in clinical developmentImpact: HighLikelihood: Medium
IGC-AD1 is still in Phase 2, so efficacy or safety issues could stop commercialization.
Exposure: IGC-AD1 and broader Alzheimer’s pipeline
- Competitive pressure in Alzheimer’s therapeuticsImpact: HighLikelihood: Medium
Larger pharmaceutical companies have more capital, development capacity, and commercialization reach.
Exposure: Alzheimer’s agitation treatment market
- Digital asset treasury volatilityImpact: MediumLikelihood: Low
Mark-to-market changes on ETP holdings can affect reported earnings and liquidity perception.
Exposure: Treasury management
- Customer and supplier concentrationImpact: Medium
A few customers and suppliers account for a meaningful share of activity, increasing disruption risk.
Exposure: Life Sciences commercial business
Accounting
Judgemental itemsProduct sales and manufacturing services may be recognized at different points in time depending on delivery and performance obligations.
Impact: Affects quarterly revenue and gross margin comparability
ETP holdings are measured at fair value with changes recognized in earnings.
Impact: Can introduce non-operating volatility in net loss
The company has recorded PPE impairment and may need further write-downs if assets are underutilized.
Impact: Can materially reduce operating results in a period
As a development-stage company, equity awards and financing instruments can be significant.
Impact: Affects operating expenses and shareholder dilution analysis
Similar listed companies
Publicly listed companies with a comparable business focus.
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Dogwood Therapeutics, Inc.
DWTX · Pharmaceutical Preparations
Voyager Therapeutics, Inc.
VYGR · Biological Products, (No Diagnostic Substances)
Coya Therapeutics, Inc.
COYA · Pharmaceutical Preparations
BioXcel Therapeutics, Inc.
BTAIQ · Pharmaceutical Preparations
IMAC Holdings, Inc.
BACK · Services-Specialty Outpatient Facilities, NEC
Last updated: 24/09/2026